Latest Conference Articles

Alan S. Brown, MD, FNLA, FACC, FAHA is a Cardiologist at Advocate Lutheran General Hospital and the President-Elect of the National Lipid Association (NLA). While at the NLA’s 2018 Scientific Sessions in Las Vegas, Nevada, he explained the connection between hypertriglyceridemia and FCS.

Alan S. Brown, MD, FNLA, FACC, FAHA, reviews emerging treatments and research for familial chylomicronemia syndrome (FCS).

Nanophotoswitches have demonstrated promising results in rats. Will they one day improve transduction in damaged eyes, and restore lost vision in humans?

The burden of ophthalmic disease is rising. How can ophthalmologists rise to meet it?

Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.

James J. Maciejko, MS, PhD, FACC, stresses the importance of rare disease awareness among physicians for proper diagnosis and treatment.

This past year, James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, President of the National Lipid Association (NLA), outlines familial chylomicronemia syndrome (FCS) and the need for treatments, which may not be far.

75% of patients with newly-diagnosed, treatment naïve DME received no treatment within 1 year of diagnosis.

At the National Lipid Association's (NLA) 2018 Scientific Sessions in LAs Vegas, NV, Wahida Karmally, MS, RD, CDE, explains the importance of nutrition and support in patients with familial chylomicronemia syndrome (FCS) and the emotional stress a strict, regimented diet can have on patients.

Voretigene neparvovec demonstrated sustained improvements in vision for patients with biallelic RPE65-mutation–associated inherited retinal disease.

Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.

Researchers hypothesized that making eye care screens free also reduced perceived value of the services.

Genentech's global head of Neuroscience clinical development detailed the company's commitment to treating the progressive form of multiple sclerosis.

An automated artificial intelligence-based system was approximately 70% accurate at predicting optimal retreatment intervals for nAMD.

The majority of eyes treated in the DRCR Protocol S study had resolved, stable or improved NV at each follow-up visit.

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

The algorithm identified PPL-HMA in 20% of eyes and was associated with a 2-3 fold increased risk of DR progression, development of PDR and receipt of intravitreal injections over 4 years.

The deep learning algorithm was tested on 71,000 images, and offers the potential to significantly increase the speed at which DR can be identified.

Clinical and biochemical assessments of LPL FCS and non-LPL FCS genes.

FCS community highlights clinical presentation and lifestyle.

Eyes that received only anti-VEGF experienced significantly worse visual acuity from initial visit to final visit.

A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.

Anti-VEGF and pan-retinal photocoagulation can be effective, but neither are "one-and-done" therapies. Physicians must be proactive about how they handle patients with PDR.

A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.

Montes' team found benefits in motor function, walking ability, and fatigue in patients to undergo nusinersen (Spinraza) for spinal muscular atrophy.

The Global Head of Neurodegeneration for Genentech talks about the progress of 2 promising monoclonal antibodies.

Treatment with volanesorsen shows efficacy in patients with FCS.